Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

• Status: Not yet recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in advanced non clear cell renal cell carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion Criteria:

• Subjects voluntarily joined the study and signed informed consent;

• Aged > 18 years;

• ECOG body status score is 0 or 1,Expected survival time is greater than 3 months.

• Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all subtypes. Patients must have advanced non-clear cell of one of the following subtypes: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified.

• Patients must have measurable lesions as defined by the RECIST 1.1 standard;

• Adequate hematologic and end-organ function as defined by the following laboratory results obtained within 28 days prior to the first study treatment:

1. Absolute neutrophil count (ANC) ≥1.5x 109/L

2. Lymphocyte count ≥ 500/uL.

3. Platelet count ≥ 80x109/L.

4. Hemoglobin ≥ 80 g/L (patients may be transfused to meet this criterion).

5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) with the following exceptions: Patients with documented liver/bone metastases should have AST and ALT ≤ 5 x ULN.

6. Serum bilirubin ≤ 1.5 x ULN.

7. Creatinine clearance ≥ 60 mL/min.

8. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective forms of contraception and to continue its use 4 weeks after the last dose of anlotinib or sintilimab.

• Signed informed consent form.

• Ability and capacity to comply with study and follow-up procedures.

Exclusion Criteria:

• Those who are known to be allergic to pharmaceutical ingredients.

• Receive anti-tumor monoclonal antibody or other research drugs within 4 weeks before enrollment; have received other anti-PD-1 antibody therapy or other treatment for PD-1/PD-L1;

• Previous use of anlotinib or other angiogenesis inhibitors

• The patient has any active autoimmune disease or a history of autoimmune disease;

• There are uncontrolled heart clinical symptoms or diseases;

• Patients with congenital or acquired immune deficiency;

• Receive chemotherapy, targeted therapy, radiotherapy within 2 weeks before enrollment;

• A history of gastrointestinal perforation or major surgery within 4 weeks before enrollment;

• Overactive/venous thrombosis occurred within 6 months prior to enrollment, such as cardiovascular-cerebral vascular (including transient ischemic attack),deep vein thrombosis (except for patients who have recovered from venous catheterization due to previous chemotherapy)and pulmonary embolism;

• Those with active bleeding or bleeding tendency;

• Presence of a drug uncontrolled hypertension;

• Urine routine indicates more than urinary protein 2+;

• Correct QT interval > 470msec; if the patient has a prolonged QT interval, but the investigator's study evaluates that the prolongation is due to a cardiac pacemaker (and no other abnormalities in the heart), it is necessary to discuss with the sponsor's researcher to determine if the patient is Suitable for group study;

• Patients suspected of having other primary cancers;

• Those who are known to be allergic to pharmaceutical ingredients.

• Patients with active or chronic hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening). Patients with past/resolved HBV infection (defined as having negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. A negative HBA DNA test must be obtained in patients with positive hepatitis B core antibody prior to Cycle 1 Day 1.

• Active hepatitis C infection. Patients positive hepatitis C antibody test are eligible if PCR is negative for hepatitis C viral DNA.

• Pregnant or lactating women.